|
May 14
|
Nuwellis Inc (NUWE) Q1 2025 Earnings Call Highlights: Strategic Growth Amidst Operational Challenges
|
|
May 13
|
Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
|
|
Nov 11
|
Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights
|
|
Nov 5
|
Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds
|
|
Jul 26
|
Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s
|
|
Jul 24
|
Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules
|
|
Jul 23
|
Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024
|
|
Jul 17
|
Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s
|
|
Jun 26
|
Nuwellis Announces Reverse Stock Split
|
|
Jun 25
|
Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™
|
|
Apr 26
|
Nuwellis Announces Pricing of $2.7 Million Public Offering
|
|
Nov 28
|
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
|
|
Nov 14
|
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|